+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Acute Myeloid Leukemia Therapeutics Market by Therapy Type, Mechanism Of Action, Line Of Therapy, End User, Route Of Administration, Patient Age - Global Forecast 2025-2030- Product Image
Acute Myeloid Leukemia Therapeutics Market by Therapy Type, Mechanism Of Action, Line Of Therapy, End User, Route Of Administration, Patient Age - Global Forecast 2025-2030- Product Image
Sale

Acute Myeloid Leukemia Therapeutics Market by Therapy Type, Mechanism Of Action, Line Of Therapy, End User, Route Of Administration, Patient Age - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 196 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 5665822
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The acute myeloid leukemia therapeutics market is experiencing sustained momentum as innovative science and evolving care models redefine pathways across drug development, market access, and patient management. Stakeholders must align strategies to capture opportunities amid dynamic technologies and regulatory changes impacting the industry.

Market Snapshot: Acute Myeloid Leukemia Therapeutics Market

The Acute Myeloid Leukemia Therapeutics Market grew from USD 1.02 billion in 2024 to USD 1.14 billion in 2025. It is expected to continue growing at a CAGR of 12.15%, reaching USD 2.03 billion by 2030.

Scope & Segmentation

  • Therapy Types: Biologics such as antibody drug conjugates, fusion proteins, and monoclonal antibodies; cell therapies including CAR T cell therapy and stem cell transplantation; gene therapies; and small molecule treatments like BCL-2 inhibitors, DNA methyltransferase inhibitors, and tyrosine kinase inhibitors targeting FLT3 and KIT mutations.
  • Mechanisms of Action: Mechanisms span BCL-2 inhibition, DNA methyltransferase inhibition, HDAC inhibition, immunomodulation, and tyrosine kinase inhibition.
  • Lines of Therapy: Segments include first-line induction, second-line consolidation, and third-line and beyond salvage strategies.
  • End Users: Hospital pharmacies handling inpatient infusions, retail pharmacies dispensing oral regimens, and specialty clinics deploying advanced cell and gene therapies.
  • Routes of Administration: Intravenous, oral, and subcutaneous delivery methods tailored for diverse patient needs and operational settings.
  • Patient Age Groups: Pediatric, adult, and geriatric cohorts, each with distinctive safety and efficacy considerations.
  • Regions: Americas (United States, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (including United Kingdom, Germany, France, Russia, GCC states, South Africa, and more), and Asia-Pacific (China, India, Japan, Australia, South Korea, and other key markets).
  • Companies Analyzed: AbbVie Inc., F. Hoffmann-La Roche Ltd, Pfizer Inc., Jazz Pharmaceuticals plc, Novartis AG, Bristol Myers Squibb Company, Astellas Pharma Inc., Agios Pharmaceuticals, Otsuka Pharmaceutical Co., Ltd., and Daiichi Sankyo Company, Limited.

Key Takeaways for Decision-Makers

  • Emerging therapies—such as immuno-oncology constructs and next-generation small molecules—offer differentiated value for patient care and are rapidly influencing market competition.
  • Integrated digital health solutions and adaptive trial designs are setting new benchmarks for real-world evidence, enhancing both clinical validation and patient engagement.
  • Collaboration across academia, biotech startups, and pharmaceutical firms is fundamentally accelerating translational research and streamlining commercialization pathways.
  • Shifts in payer expectations and reimbursement frameworks are intensifying the need for robust health economic data and head-to-head clinical comparisons.
  • Adaptation to regional regulatory requirements, infrastructure maturity, and decentralized trial models is crucial for efficient product launches and long-term growth.
  • Focus on biomarker-driven strategies and precision monitoring tools is transforming efficacy endpoints and shaping the future of AML therapeutics.

Tariff Impact: Navigating Supply Chain Resilience

  • New tariff measures on pharmaceutical imports and raw materials are prompting manufacturers to localize production and form strategic partnerships with domestic organizations.
  • Material cost volatility and sourcing challenges are driving comprehensive risk assessments of global supply networks, while near-shoring and value chain optimization are gaining traction.
  • Industry collaboration with trade and regulatory agencies is expediting customs processes to ensure consistent patient access and market competitiveness.

Methodology & Data Sources

This analysis is anchored in a mixed-methods approach, integrating primary interviews with industry experts and key opinion leaders with a thorough review of peer-reviewed journals, regulatory filings, and company disclosures. Analytical techniques such as thematic analysis, SWOT assessments, and triangulation ensure robust, actionable insights tailored for senior decision-makers.

Why This Report Matters

  • Informs strategic planning by mapping technology, regulatory, and market shifts within the acute myeloid leukemia therapeutics market.
  • Equips leadership with validated insights on competitive landscape, supply chain vulnerabilities, and regional growth strategies.
  • Supports investment decisions with current intelligence on R&D, commercialization, and operational best practices.

Conclusion

Stakeholders leveraging these insights can anticipate market shifts, minimize risk, and advance acute myeloid leukemia therapeutics. An informed, holistic approach is vital for securing sustained growth and improving patient outcomes.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Emergence of FLT3 inhibitors in frontline and relapsed/refractory AML treatment landscape with improved survival outcomes
5.2. Expansion of menin inhibitors targeting MLL-rearranged and NPM1-mutant acute myeloid leukemia in clinical trials
5.3. Development of bispecific T-cell engagers against CD33 and CD123 antigens driving immunotherapy innovation in AML
5.4. Integration of MRD-guided therapy adjustments using next-generation sequencing to personalize AML treatment strategies
5.5. Approval and commercialization of oral BCL-2 inhibitor regimens offering chemo-free options for elderly AML patients
5.6. Investigation of CAR-T cell therapies targeting AML-specific antigens to overcome treatment resistance in relapsed cases
5.7. Adoption of targeted epigenetic modulators like IDH1/2 inhibitors shaping the therapeutic paradigm in AML management
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Acute Myeloid Leukemia Therapeutics Market, by Therapy Type
8.1. Introduction
8.2. Biologic
8.2.1. Antibody Drug Conjugates
8.2.2. Fusion Proteins
8.2.3. Monoclonal Antibodies
8.3. Cell Therapy
8.3.1. CAR T Cell Therapy
8.3.2. Stem Cell Transplantation
8.4. Gene Therapy
8.5. Small Molecule
8.5.1. BCL-2 Inhibitors
8.5.2. DNA Methyltransferase Inhibitors
8.5.3. Tyrosine Kinase Inhibitors
8.5.3.1. FLT3 Inhibitors
8.5.3.2. KIT Inhibitors
9. Acute Myeloid Leukemia Therapeutics Market, by Mechanism Of Action
9.1. Introduction
9.2. BCL-2 Inhibitors
9.3. DNA Methyltransferase Inhibitors
9.4. HDAC Inhibitors
9.5. Immunomodulatory Agents
9.6. Tyrosine Kinase Inhibitors
10. Acute Myeloid Leukemia Therapeutics Market, by Line Of Therapy
10.1. Introduction
10.2. First Line
10.3. Second Line
10.4. Third Line And Beyond
11. Acute Myeloid Leukemia Therapeutics Market, by End User
11.1. Introduction
11.2. Hospital Pharmacy
11.3. Retail Pharmacy
11.4. Specialty Clinic
12. Acute Myeloid Leukemia Therapeutics Market, by Route Of Administration
12.1. Introduction
12.2. Intravenous
12.3. Oral
12.4. Subcutaneous
13. Acute Myeloid Leukemia Therapeutics Market, by Patient Age
13.1. Introduction
13.2. Adult
13.3. Geriatric
13.4. Pediatric
14. Americas Acute Myeloid Leukemia Therapeutics Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Acute Myeloid Leukemia Therapeutics Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Acute Myeloid Leukemia Therapeutics Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. AbbVie Inc.
17.3.2. F. Hoffmann-La Roche Ltd
17.3.3. Pfizer Inc.
17.3.4. Jazz Pharmaceuticals plc
17.3.5. Novartis AG
17.3.6. Bristol Myers Squibb Company
17.3.7. Astellas Pharma Inc.
17.3.8. Agios Pharmaceuticals, Inc.
17.3.9. Otsuka Pharmaceutical Co., Ltd.
17.3.10. Daiichi Sankyo Company, Limited
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2030 (%)
FIGURE 10. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE, 2024 VS 2030 (%)
FIGURE 16. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 27. ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET: RESEARCHAI
FIGURE 28. ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET: RESEARCHSTATISTICS
FIGURE 29. ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET: RESEARCHCONTACTS
FIGURE 30. ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BIOLOGIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BIOLOGIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY FUSION PROTEINS, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY FUSION PROTEINS, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BIOLOGIC, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BIOLOGIC, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CELL THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CAR T CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CAR T CELL THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY STEM CELL TRANSPLANTATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY STEM CELL TRANSPLANTATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CELL THERAPY, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CELL THERAPY, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BCL-2 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BCL-2 INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY FLT3 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY FLT3 INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY KIT INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY KIT INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BCL-2 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BCL-2 INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY HDAC INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY HDAC INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY IMMUNOMODULATORY AGENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY IMMUNOMODULATORY AGENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY FIRST LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SECOND LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THIRD LINE AND BEYOND, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THIRD LINE AND BEYOND, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ADULT, BY REGION, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY GERIATRIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 91. AMERICAS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 92. AMERICAS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 93. AMERICAS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BIOLOGIC, 2018-2024 (USD MILLION)
TABLE 94. AMERICAS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BIOLOGIC, 2025-2030 (USD MILLION)
TABLE 95. AMERICAS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CELL THERAPY, 2018-2024 (USD MILLION)
TABLE 96. AMERICAS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CELL THERAPY, 2025-2030 (USD MILLION)
TABLE 97. AMERICAS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE, 2018-2024 (USD MILLION)
TABLE 98. AMERICAS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE, 2025-2030 (USD MILLION)
TABLE 99. AMERICAS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 100. AMERICAS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 101. AMERICAS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 102. AMERICAS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 103. AMERICAS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 104. AMERICAS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 105. AMERICAS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 106. AMERICAS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 107. AMERICAS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 108. AMERICAS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 109. AMERICAS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
TABLE 110. AMERICAS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE, 2025-2030 (USD MILLION)
TABLE 111. AMERICAS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 112. AMERICAS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 113. UNITED STATES ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 114. UNITED STATES ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 115. UNITED STATES ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BIOLOGIC, 2018-2024 (USD MILLION)
TABLE 116. UNITED STATES ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BIOLOGIC, 2025-2030 (USD MILLION)
TABLE 117. UNITED STATES ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CELL THERAPY, 2018-2024 (USD MILLION)
TABLE 118. UNITED STATES ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CELL THERAPY, 2025-2030 (USD MILLION)
TABLE 119. UNITED STATES ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE, 2018-2024 (USD MILLION)
TABLE 120. UNITED STATES ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE, 2025-2030 (USD MILLION)
TABLE 121. UNITED STATES ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 122. UNITED STATES ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 123. UNITED STATES ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 124. UNITED STATES ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 125. UNITED STATES ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 126. UNITED STATES ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 127. UNITED STATES ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 128. UNITED STATES ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 129. UNITED STATES ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 130. UNITED STATES ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 131. UNITED STATES ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
TABLE 132. UNITED STATES ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE, 2025-2030 (USD MILLION)
TABLE 133. UNITED STATES ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 134. UNITED STATES ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 135. CANADA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 136. CANADA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 137. CANADA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BIOLOGIC, 2018-2024 (USD MILLION)
TABLE 138. CANADA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BIOLOGIC, 2025-2030 (USD MILLION)
TABLE 139. CANADA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CELL THERAPY, 2018-2024 (USD MILLION)
TABLE 140. CANADA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CELL THERAPY, 2025-2030 (USD MILLION)
TABLE 141. CANADA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE, 2018-2024 (USD MILLION)
TABLE 142. CANADA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE, 2025-2030 (USD MILLION)
TABLE 143. CANADA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 144. CANADA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 145. CANADA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 146. CANADA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 147. CANADA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 148. CANADA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 149. CANADA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 150. CANADA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 151. CANADA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 152. CANADA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 153. CANADA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
TABLE 154. CANADA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE, 2025-2030 (USD MILLION)
TABLE 155. MEXICO ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 156. MEXICO ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 157. MEXICO ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BIOLOGIC, 2018-2024 (USD MILLION)
TABLE 158. MEXICO ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BIOLOGIC, 2025-2030 (USD MILLION)
TABLE 159. MEXICO ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CELL THERAPY, 2018-2024 (USD MILLION)
TABLE 160. MEXICO ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CELL THERAPY, 2025-2030 (USD MILLION)
TABLE 161. MEXICO ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE, 2018-2024 (USD MILLION)
TABLE 162. MEXICO ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE, 2025-2030 (USD MILLION)
TABLE 163. MEXICO ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 164. MEXICO ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 165. MEXICO ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 166. MEXICO ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 167. MEXICO ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 168. MEXICO ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 169. MEXICO ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 170. MEXICO ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 171. MEXICO ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 172. MEXICO ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 173. MEXICO ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
TABLE 174. MEXICO ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE, 2025-2030 (USD MILLION)
TABLE 175. BRAZIL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 176. BRAZIL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 177. BRAZIL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BIOLOGIC, 2018-2024 (USD MILLION)
TABLE 178. BRAZIL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BIOLOGIC, 2025-2030 (USD MILLION)
TABLE 179. BRAZIL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CELL THERAPY, 2018-2024 (USD MILLION)
TABLE 180. BRAZIL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CELL THERAPY, 2025-2030 (USD MILLION)
TABLE 181. BRAZIL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE, 2018-2024 (USD MILLION)
TABLE 182. BRAZIL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE, 2025-2030 (USD MILLION)
TABLE 183. BRAZIL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 184. BRAZIL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 185. BRAZIL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 186. BRAZIL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 187. BRAZIL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 188. BRAZIL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 189. BRAZIL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 190. BRAZIL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 191. BRAZIL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 192. BRAZIL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 193. BRAZIL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
TABLE 194. BRAZIL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE, 2025-2030 (USD MILLION)
TABLE 195. ARGENTINA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 196. ARGENTINA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 197. ARGENTINA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BIOLOGIC, 2018-2024 (USD MILLION)
TABLE 198. ARGENTINA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BIOLOGIC, 2025-2030 (USD MILLION)
TABLE 199. ARGENTINA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CELL THERAPY, 2018-2024 (USD MILLION)
TABLE 200. ARGENTINA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CELL THERAPY, 2025-2030 (USD MILLION)
TABLE 201. ARGENTINA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE, 2018-2024 (USD MILLION)
TABLE 202. ARGENTINA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE, 2025-2030 (USD MILLION)
TABLE 203. ARGENTINA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 204. ARGENTINA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 205. ARGENTINA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 206. ARGENTINA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 207. ARGENTINA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 208. ARGENTINA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 209. ARGENTINA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 210. ARGENTINA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 211. ARGENTINA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 212. ARGENTINA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 213. ARGENTINA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
TABLE 214. ARGENTINA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE, 2025-2030 (USD MILLION)
TABLE 215. EUROPE, MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 216. EUROPE, MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 217. EUROPE, MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BIOLOGIC, 2018-2024 (USD MILLION)
TABLE 218. EUROPE, MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BIOLOGIC, 2025-2030 (USD MILLION)
TABLE 219. EUROPE, MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CELL THERAPY, 2018-2024 (USD MILLION)
TABLE 220. EUROPE, MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CELL THERAPY, 2025-2030 (USD MILLION)
TABLE 221. EUROPE, MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE, 2018-2024 (USD MILLION)
TABLE 222. EUROPE, MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE, 2025-2030 (USD MILLION)
TABLE 223. EUROPE, MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 224. EUROPE, MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 225. EUROPE, MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 226. EUROPE, MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 227. EUROPE, MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 228. EUROPE, MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 229. EUROPE, MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 230. EUROPE, MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 231. EUROPE, MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 232. EUROPE, MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 233. EUROPE, MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
TABLE 234. EUROPE, MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE, 2025-2030 (USD MILLION)
TABLE 235. EUROPE, MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 236. EUROPE, MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 237. UNITED KINGDOM ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 238. UNITED KINGDOM ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 239. UNITED KINGDOM ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BIOLOGIC, 2018-2024 (USD MILLION)
TABLE 240. UNITED KINGDOM ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BIOLOGIC, 2025-2030 (USD MILLION)
TABLE 241. UNITED KINGDOM ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CELL THERAPY, 2018-2024 (USD MILLION)
TABLE 242. UNITED KINGDOM ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CELL THERAPY, 2025-2030 (USD MILLION)
TABLE 243. UNITED KINGDOM ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE, 2018-2024 (USD MILLION)
TABLE 244. UNITED KINGDOM ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE, 2025-2030 (USD MILLION)
TABLE 245. UNITED KINGDOM ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 246. UNITED KINGDOM ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 247. UNITED KINGDOM ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 248. UNITED KINGDOM ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 249. UNITED KINGDOM ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 250. UNITED KINGDOM ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 251. UNITED KINGDOM ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 252. UNITED KINGDOM ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 253. UNITED KINGDOM ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 254. UNITED KINGDOM ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 255. UNITED KINGDOM ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
TABLE 256. UNITED KINGDOM ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE, 2025-2030 (USD MILLION)
TABLE 257. GERMANY ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 258. GERMANY ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 259. GERMANY ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BIOLOGIC, 2018-2024 (USD MILLION)
TABLE 260. GERMANY ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BIOLOGIC, 2025-2030 (USD MILLION)
TABLE 261. GERMANY ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CELL THERAPY, 2018-2024 (USD MILLION)
TABLE 262. GERMANY ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CELL THERAPY, 2025-2030 (USD MILLION)
TABLE 263. GERMANY ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE, 2018-2024 (USD MILLION)
TABLE 264. GERMANY ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE, 2025-2030 (USD MILLION)
TABLE 265. GERMANY ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 266. GERMANY ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 267. GERMANY ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 268. GERMANY ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 269. GERMANY ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 270. GERMANY ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 271. GERMANY ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 272. GERMANY ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 273. GERMANY ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 274. GERMANY ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 275. GERMANY ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
TABLE 276. GERMANY ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE, 2025-2030 (USD MILLION)
TABLE 277. FRANCE ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 278. FRANCE ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 279. FRANCE ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BIOLOGIC, 2018-2024 (USD MILLION)
TABLE 280. FRANCE ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BIOLOGIC, 2025-2030 (USD MILLION)
TABLE 281. FRANCE ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CELL THERAPY, 2018-2024 (USD MILLION)
TABLE 282. FRANCE ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CELL THERAPY, 2025-2030 (USD MILLION)
TABLE 283. FRANCE ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE, 2018-2024 (USD MILLION)
TABLE 284. FRANCE ACUTE MYELOID LEUKEMIA THERAPEUTICS MARK

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Acute Myeloid Leukemia Therapeutics market report include:
  • AbbVie Inc.
  • F. Hoffmann-La Roche Ltd
  • Pfizer Inc.
  • Jazz Pharmaceuticals plc
  • Novartis AG
  • Bristol Myers Squibb Company
  • Astellas Pharma Inc.
  • Agios Pharmaceuticals, Inc.
  • Otsuka Pharmaceutical Co., Ltd.
  • Daiichi Sankyo Company, Limited

Table Information

Report AttributeDetails
No. of Pages196
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 1.14 Billion
Forecasted Market Value ( USD ) by 2030 $ 2.03 Billion
Compound Annual Growth Rate12.1%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Acute Myeloid Leukemia (AML) Therapeutics - Global Strategic Business Report - Product Image

Acute Myeloid Leukemia (AML) Therapeutics - Global Strategic Business Report

  • Report
  • 356 Pages
  • Global
From
2025 Global Forecast for Acute Myeloid Leukemia Treatment Market (2026-2031 Outlook)-High Tech Outlook Report - Product Image

2025 Global Forecast for Acute Myeloid Leukemia Treatment Market (2026-2031 Outlook)-High Tech Outlook Report

  • Report
  • 132 Pages
  • Global
From
Leukemia Targeted Therapy Drugs Market by Therapy Class, Indication, Line Of Therapy, Route Of Administration, Patient Age Group, Distribution Channel - Global Forecast 2025-2030 - Product Image

Leukemia Targeted Therapy Drugs Market by Therapy Class, Indication, Line Of Therapy, Route Of Administration, Patient Age Group, Distribution Channel - Global Forecast 2025-2030

  • Report
  • 186 Pages
  • Global
From
Acute Myeloid Leukemia Market Report 2025 - Product Image

Acute Myeloid Leukemia Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Leukemia Therapeutics Market by Type, Mechanism of Action, Line of Therapy, Route of Administration, Age Group, End-User - Global Forecast 2025-2030 - Product Image

Leukemia Therapeutics Market by Type, Mechanism of Action, Line of Therapy, Route of Administration, Age Group, End-User - Global Forecast 2025-2030

  • Report
  • 192 Pages
  • Global
From

About the Acute Myeloid Leukemia Drug Market

Acute Myeloid Leukemia (AML) is a type of cancer that affects the blood and bone marrow. It is the most common type of acute leukemia in adults. Treatment for AML typically involves chemotherapy, radiation therapy, and stem cell transplantation. Drugs used to treat AML include cytarabine, daunorubicin, and idarubicin. These drugs are used to kill cancer cells, reduce the size of tumors, and reduce the risk of relapse. Other drugs used to treat AML include decitabine, gemtuzumab ozogamicin, and venetoclax. These drugs are used to target specific genetic mutations that are associated with AML. The AML drug market is highly competitive, with many companies offering a variety of treatments. Some of the major players in the market include Novartis, Pfizer, Celgene, Bristol-Myers Squibb, and Merck. Other companies in the market include AbbVie, AstraZeneca, Johnson & Johnson, and Sanofi. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.